Provided by Tiger Fintech (Singapore) Pte. Ltd.

Acelyrin, Inc.

2.47
+0.02000.82%
Post-market: 2.470.00000.00%18:20 EDT
Volume:366.50K
Turnover:899.32K
Market Cap:248.75M
PE:-0.99
High:2.50
Open:2.42
Low:2.39
Close:2.45
Loading ...

Company Profile

Company Name:
Acelyrin, Inc.
Exchange:
NASDAQ
Establishment Date:
2020
Employees:
83
Office Location:
4149 Liberty Canyon Road,Agoura Hills,California,United States
Zip Code:
91301
Fax:
- -
Introduction:
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.

Directors

Name
Position
Shao Lee Lin
Founder, Chief Executive Officer and Director
Bruce C. Cozadd
Chair and Director
Alan Colowick
Director
Beth Seidenberg
Director
Dan Becker
Director
Dawn Svoronos
Director
Henry O. Gosebruch
Director
Patrick Machado
Director

Shareholders

Name
Position
Shao Lee Lin
Founder, Chief Executive Officer and Director
Melanie Gloria
Chief Operating Officer
Mardi C. Dier
Chief Financial Officer and Chief Business Officer
Mina Kim
Chief Legal and Administrative Officer
Paul M. Peloso
Chief Medical Officer
Ron Oyston
Chief People Officer